CLASS ACTION UPDATE for FSCT, GERN and TUP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / February 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Forescout Technologies, Inc. (NASDAQ:FSCT)
FSCT Lawsuit on behalf of: investors who purchased February 7, 2019 – October 9, 2019
Lead Plaintiff Deadline: March 2, 2020
Join the action: https://www.zlk.com/pslra-1/forescout-technologies-inc-loss-form?wire=3&prid=5528
About the FSCT lawsuit: Throughout the class period, Forescout Technologies, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Forescout was experiencing significant volatility with respect to large deals and issues related to the timing and execution of deals in the Company's pipeline, especially in Europe, the Middle East, and Africa; (ii) the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more about the Forescout Technologies, Inc. class action, contact jlevi@levikorsinsky.com.
Geron Corporation (NASDAQ:GERN)
GERN Lawsuit on behalf of: investors who purchased March 19, 2018 – September 26, 2018
Lead Plaintiff Deadline: March 23, 2020
Join the action: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?wire=3&prid=5528
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
To learn more about the Geron Corporation class action, contact jlevi@levikorsinsky.com.
Tupperware Brands Corporation (NYSE:TUP)
TUP Lawsuit on behalf of: investors who purchased January 30, 2019 – February 24, 2020
Lead Plaintiff Deadline: April 27, 2020
Join the action: https://www.zlk.com/pslra-1/tupperware-brands-corporation-loss-form?wire=3&prid=5528
About the TUP lawsuit: Tupperware Brands Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Tupperware lacked effective internal controls; (2) as a result, Tupperware would need to investigate the accounting and liabilities of one of its brands, Fuller Mexico; (3) consequently, Tupperware would be unable to timely file its annual report on Form 10-K for its fiscal year 2019; (4) Tupperware did not properly account for its accounts payable and accrued liabilities at Fuller Mexico; (5) Tupperware provided overvalued earnings per share guidance; (6) Tupperware would need relief from its $650 million Credit Agreement; and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times.
To learn more about the Tupperware Brands Corporation class action, contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky LLP
ReleaseID: 578038